Compounding the problem is the fact that insurance companies are reluctant to cover these anti-obesity medications, since theyre considered by many to be vanity drugs, even though overwhelming evidence suggests obesity is linked directly to multiple comorbidities
Rocio Pereira, MD, chief of Endocrinology at the safety-net hospital system Denver Health and an associate professor of medicine at the University of Colorado, says that many of her patients report that semaglutide helps them eat less and that it has become easier for them to eat healthy foods and avoid junk food since starting on the medication
As patients lose weight and metabolic control improves, clinicians should reassess concurrent therapies to reduce the risk of hypoglycemia and polypharmacy, particularly when insulin or sulfonylureas are used
Other Innovative Solutions To further support our clients and their members, we created our Diabetes Care Plus program
As shortages of brand-name GLP-1 medications begin to ease, regulators are increasing scrutiny on these platforms to ensure patient safety and compliance, signaling a broader crackdown on unapproved or gray-market weight-loss treatments
Obesity prevalence has doubled since 1990, with one in eight individuals being obese worldwide
